A small inhibitor of the interaction between Bax and Bcl-XL can synergize with methylprednisolone to induce apoptosis in Bcl-X L-overexpressing breast-cancer cells

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 8, 2003, Pages 437-448

  Tan, Yee Joo ^a   Teng, Eileen ^a   Ting, Anthony E ^a,b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b ATHERSYS INC   (United States)

Author keywords

Apoptosis; Bcl 2 family; Chemoresistance; Methylprednisolone; Synergism

Indexed keywords

2',4',5',7' TETRABROMOFLUORESCEIN; 3,4,5,6 TETRABROMOFLUORESCEIN; 4',5' DIBROMOFLUORESCEIN; ANTINEOPLASTIC AGENT; BROMINE DERIVATIVE; CYCLOHEXIMIDE; DEXAMETHASONE; FLUORESCEIN DERIVATIVE; METHYLPREDNISOLONE; PROTEIN BAX; PROTEIN BCL XL; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL STRAIN MCF 7; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG RESISTANCE; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; DRUG SYNERGISM; EOSINE YELLOWISH-(YS); FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHYLPREDNISOLONE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0041853138     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0464-4     Document Type: Article

References (75)

1. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326
2. Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26:61-66
3. Agrawal S (1996) Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 14:376-387
4. Atkins PW (1986) Physical chemistry, 3rd edn. Oxford University Press, Oxford, 857pp
5. Baba M, Iishi H, Tatsuta M (2000) In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats. Int J Cancer 85:260-266
6. Banerjee D (1999) Technology evaluation: G3139. Curr Opin Mol Therapeutics 1:404-408
7. Beerheide W, Tan Y-J, Teng E, Ting AE, Jedpiyawongse A, Srivatanakul P (2000) Downregulation of pro-apoptotic proteins Bax and Bcl-X(S) in p53 overexpressing liver tumors. Biochem Biophys Res Commun 273:54-61
8. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93-141
9. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608
10. Brennan TM, Taylor DL, Bridges CG, Leyda JP, Tyms AS (1995) The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res 26:173-187
11. Broome HE, Yu AL, Diccianni M, Camitta BM, Monia BP, Dean NM (2002) Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. Leuk Res 26:311-316
12. Caldwell JR (1996) Intra-articular corticosteroids. Guide to selection and indications for use. Drugs 52:507-514
13. Campos L, Sabido O, Rouault J-P, Guyotat D (1994) Effects of BCL-2 antisense oligodeoxynucleotides on in vitro cell proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595-600
14. Chao D, Korsmeyer S (1998) BCL-2 family: regulators of cell death. Annu Rev Immunol 16:395-419
15. Cohen JJ (1989) Lymphocyte death induced by glucocorticoids. In: Schlemer RP, Claman HN, Oronsky A (eds) Anti-inflammatory steroid action: basic and clinical aspects. Academic Press, San Diego, pp 110-131
16. Cohen JJ (1992) Glucocorticoids. In: Roitt IM, Delves PJ (eds) Encyclopaedia of immunology. Sanders, London, pp 616-617
17. Cooper MA (2002) Optical biosensors in drug discovery. Natl Rev Drug Discov 1:515-528
18. Cotter FE, Johnson P, Hall P. Pocock C, al Mahdi N, Cowell JK, Morgan G (1994) Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9:3049-3055
19. Craig RW (1995) The bcl-2 gene family. Semin Cancer Biol 6:35-43
20. Desoize B (1994) Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14:2291-2294
21. Eastman A (1993) Apoptosis: a product of programmed and unprogrammed cell death. Toxicol Appl Pharmacol 121:160-164
22. Fivash M, Towler EM, Fisher RJ (1998) BIAcore for macromolecular interaction. Curr Opin Biotechnol 9:97-101
23. Gewirtz AM (2000) Oligonucleotide therapeutics: a step forward. J Clin Oncol 18:1809-1811
24. Gewirtz AM, Stein CA, Glazer PM (1996) Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci U S A 93:3161-3163
25. Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911
26. Hardman JG, Limbird LE (eds-in-chief) (1996) Goodman & Gilman's The pharmacological basis of therapeutics, 9th edn. McGraw-Hill, 1905 pp
27. Hickman JA (1992) Apoptosis induced by anticancer agents. Cancer Metastasis Rev 11:121-139
28. Hicsonmez G, Ozsoylu S, Tuncer AM (1991) Differentiation of myeloid leukemic cells induced by high-dose methylprednisolone in patients with acute myeloblastic leukaemia and its therapeutic potential. Leuk Res 15:537-541
29. Hockenbery DM (1994) bcl-2 in cancer, development and apoptosis. J Cell Sci Suppl 18:51-55
30. Huang Z (2000) Bcl-2 family proteins as targets for anti-cancer drug design. Oncogene 19:6627-6631
31. Huang Z (2002) The chemical biology of apoptosis: exploring protein-protein interactions and the life and death of cells with small molecules. Chem Biol 9:1059-1072
32. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-234
33. Jönsson U, Fägerstam L, Ivarsson B, Johnsson B, Karlsson R, Lundh K, Löfås S, Persson B, Roos H, Rönnberg I, Sjölander S, Stenberg E, et al. (1991) Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 11:620-627
34. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC (1994) Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4:71-79
35. Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3:614-620
36. Laan RF, Jansen TL, van Riel PL (1999) Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology (Oxford) 38:6-12
37. Lebedeva I, Stein CA (2001) Antisense oligonucleotides: promise and reality. Ann Rev Pharmacol Toxicol 41:403-419
38. Leech SH, Olie RA, Gautschi O, Simoes-Wust AP, Tschopp S, Haner R, Hall J, Stahel RA, Zangemeister-Wittke U (2000) Induction of apoptosis in lung cancer cells following bcl-xL antisense treatment. Int J Cancer 86:570-576
39. Leung S, Miyake H, Zellwager T, Tolcher A, Gleave ME (2001) Synergistic chemosensitization and inhibition of progression to androgen independence by anti-sense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 91:846-850
40. Malmqvist M (1993) Surface plasmon resonance for detection and measurement of antibody-antigen affinity and kinetics. Curr Opin Immunol 5:282-286
41. Miayake H, Tolcher A, Gleave ME (2000) Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of anti-sense Bcl-2 oligodeoxynucleotides J Natl Cancer Inst 92:34-41
42. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M (2002) Simultaneous disruption of the Bcl-2 and MEK/MAPK pathways synergistically induces apoptosis in acute myelogenous leukemia. Blood 99:3461-3464
43. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW (1996) X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381:335-341
44. Nicholson DW (2000) From bench to clinic with apoptosis-based therapeutic agents. Nature 407:810-816
45. Ogura E, Senzaki H, Yamamoto D, Yoshida R, Takada H, Hioki K, Tsubura A (1999) Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol Rep 6:365-369
46. Opalinska JB, Gerwirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Natl Rev Drug Discov 1:503-514
47. Ozsoylu S (2001) Megadose methylprednisolone for granulocytic sarcoma. Acta Haematol 105:118
48. Patel T, Gores GJ, Kaufmann SH (1996) The role of proteases during apoptosis. FASEB J 10:587-597
49. Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, Mack J, Swift K, Matayoshi ED, Zhang H, Thompson CB, Fesik SW (2000) Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9:2528-2534
50. Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE (1997) Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281:420-427
51. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6
52. Reed JC (1995a) Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 82/83:155-158
53. Reed JC (1995b) Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541-546
54. Reed JC (1995c) Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9:451-473
55. Reed JC (1997a) Double identity for proteins of the Bcl-2 family. Nature 387:773-776
56. Reed JC (1997b) Editorials: promise and problems of Bcl-2 antisense therapy. J Natl Cancer Inst 89:988-990
57. Reed JC (1998) Bcl-2 family proteins. Oncogene 17:3225-3236
58. Reed JC (1999) Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1:68-75
59. Sattler M, Liang H, Nettesheim D, Meadows R, Harlan JE, Eberstadt M, Yoon H, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW (1997) Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275:983-986
60. Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, Pehamberger H, Jansen B (2000) Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 114:725-730
61. Suhnel J (1990) Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res 13:23-39
62. L. Protein Eng 13:887-892
63. Tan Y-J, Beerheide W, Ting AE (1999) Biophysical characterization of the oligomeric state of Bax and its complex formation with Bcl-XL. Biochem Biophys Res Commun 255:334-339
64. Taylor JK, Zhang QQ, Wyatt JR, Dean NM (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 17:1097-1100
65. Tsujimoto Y, Shimizu S (2000) Bcl-2 family: life-or-death switch. FEBS Lett 466:6-10
66. Tsujimoto Y, Cossmann J, Jaffe E, Croce CM (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443
67. van Oosten BW, Truyen L, Barkhof F, Polman CH (1998) Choosing drug therapy for multiple sclerosis. An update. Drugs 56:555-569
68. Vander Heiden MG, Thompson CB (1999) Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1:E209-216
69. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 97:7124-7129
70. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE (2000) Phase I clinical and pharmacokinetics study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823
71. Webb A, Cunningham D, Cotter F, Clarke P, di Stefano F, Ross P, Corbo M, Dziewanowska Z (1997) Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137-1141
72. Yamaguchi H, Paranawithana SR, Lee MW, Huang ZW, Bhalla, KN, Wang HG (2002) Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 62:466-471
73. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxy-nucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78:1035-1042
74. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH, Natt F, Haner R, Martin P, Hall J, Nalin CM, Stahel RA (2000) A novel biospecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 6:2547-2555
75. Zheng XM, Wang Y, Pallen CJ (1992) Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature 359:336-339